» Articles » PMID: 12562380

Endogenous Glucocorticoids Attenuate Shiga Toxin-2-induced Toxicity in a Mouse Model of Haemolytic Uraemic Syndrome

Overview
Date 2003 Feb 4
PMID 12562380
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The concept that during an immune challenge the release of glucocorticoids (GC) provides feedback inhibition on evolving immune responses has been drawn primarily from studies of autoimmune and/or inflammatory processes in animal models. The epidemic form of haemolytic uraemic syndrome (HUS) occurs secondary to infection with Gram-negative bacteria that produce Shiga toxin (Stx). Although Stx binding to the specific receptors present on renal tissue is the primary pathogenic mechanism, inflammatory or immune interactions are necessary for the development of the complete form of HUS. The aim of this study was to investigate the influence of endogenous GC on Stx-toxicity in a mouse model. Stx2 was injected into GC-deprived mice and survival rate, renal damage and serum urea levels were evaluated. Plasma corticosterone and cytosolic GC receptor (GR) concentration were also determined at multiple intervals post-Stx2 treatment. Higher sensitivity to Stx2 was observed in mice lacking endogenous GC, evidenced by an increase in mortality rates, circulating urea levels and renal histological damage. Moreover, Stx2 injection was associated with a transient but significant rise in corticosterone secretion. Interestingly, 24 h after Stx inoculation significant increases in total GR were detected in circulating neutrophils. These results indicate that interactions between the neuroendocrine and immune systems can modulate the level of damage significantly during a bacterial infection.

Citing Articles

Evolutionary Significance of the Neuroendocrine Stress Axis on Vertebrate Immunity and the Influence of the Microbiome on Early-Life Stress Regulation and Health Outcomes.

Ortega V, Mercer E, Giesbrecht G, Arrieta M Front Microbiol. 2021; 12:634539.

PMID: 33897639 PMC: 8058197. DOI: 10.3389/fmicb.2021.634539.


Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic .

Goldstein J, Nunez-Goluboay K, Pinto A Curr Neuropharmacol. 2020; 19(1):24-44.

PMID: 32077828 PMC: 7903495. DOI: 10.2174/1570159X18666200220143001.


Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Exeni R, Fernandez-Brando R, Santiago A, Fiorentino G, Exeni A, Ramos M Pediatr Nephrol. 2018; 33(11):2057-2071.

PMID: 29372302 DOI: 10.1007/s00467-017-3876-0.


Role of transcriptional coregulator GRIP1 in the anti-inflammatory actions of glucocorticoids.

Chinenov Y, Gupte R, Dobrovolna J, Flammer J, Liu B, Michelassi F Proc Natl Acad Sci U S A. 2012; 109(29):11776-81.

PMID: 22753499 PMC: 3406827. DOI: 10.1073/pnas.1206059109.


The glucocorticoid receptor: a revisited target for toxins.

Webster Marketon J, Sternberg E Toxins (Basel). 2011; 2(6):1357-80.

PMID: 22069642 PMC: 3153245. DOI: 10.3390/toxins2061357.


References
1.
Middelveld R, Wanecek M, Bergman D, Weitzberg E, Alving K . Effect of cortisol-synthesis inhibition on endotoxin-induced porcine acute lung injury, shock, and nitric oxide production. Shock. 1999; 12(5):382-90. DOI: 10.1097/00024382-199911000-00007. View

2.
Paton J, Paton A . Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev. 1998; 11(3):450-79. PMC: 88891. DOI: 10.1128/CMR.11.3.450. View

3.
te Loo D, Monnens L, van Der Velden T, Vermeer M, Preyers F, Demacker P . Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood. 2000; 95(11):3396-402. View

4.
Fernandez G, Rubel C, Dran G, Gomez S, Isturiz M, Palermo M . Shiga toxin-2 induces neutrophilia and neutrophil activation in a murine model of hemolytic uremic syndrome. Clin Immunol. 2000; 95(3):227-34. DOI: 10.1006/clim.2000.4862. View

5.
Foster G, Armstrong C, Sakiri R, Tesh V . Shiga toxin-induced tumor necrosis factor alpha expression: requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases. Infect Immun. 2000; 68(9):5183-9. PMC: 101776. DOI: 10.1128/IAI.68.9.5183-5189.2000. View